Dasatinib
Cat. No.：YN440045
CAS No. ：302962-49-8
规格
价格(RMB)
库存
| 产品名称: | Dasatinib |
| CAS No.: | 302962-49-8 |
| Chemical Name: | N-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1-piperazinyl]-2-methyl-4-pyrimidinyl]amino]-5-thiazolecarboxamide |
| Synonyms: | 达沙替尼; BMS-354825 |
| 分子量: | 488.01 |
| 分子式: | C₂₂H₂₆ClN₇O₂S |
| SMILES: | O=C(C1=CN=C(S1)NC2=NC(C)=NC(N3CCN(CC3)CCO)=C2)NC4=C(C=CC=C4Cl)C |
| 存储: | Please store the product under the recommended conditions in theCertificate of Analysis. |
| 运输: | Room temperature in continental US; may vary elsewhere. |
| 产品描述: | Dasatinib (BMS-354825) 是一种具有口服活性的，ATP 竞争性的，双重Src/Bcr-Abl抑制剂，具有有效的抗肿瘤活性。对 Src 和 Bcr-Abl 的Ki值分别为 16 pM 和 30 pM。 |
| IC50和靶点: | [{name:"Bcr-Abl:1.0 nM (IC50)"},{name: "Src:0.5 nM (IC50)"},{name: "lck:0.4 nM (IC50)"},{name: "yes:0.5 nM (IC50)"},{name: "c-kit:5.0 nM (IC50)"},{name: "PDGFRβ:28 nM (IC50)"},{name: "p38:100 nM (IC50)"},{name: "Her1:180 nM (IC50)"},{name: "Her2:710 nM (IC50)"},{name: "FGFR-1:880 nM (IC50)"},{name: "MEK:1700 nM (IC50)"}] |
| In Vitro: | |
| In Vivo: | |
| Clinical Trial: | |
| Solvent & Solubility: |
Lombardo, L.J., Lee, F.Y., Chen, P., et al.Discovery of N-(2-chloro-6-methyl-phenyl)-2-(6-(4-(2-hydroxyethyl)-piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide (BMS-354825),a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assaysJ. Med. Chem.47(27),6658-6661(2004)
Das, J., Chen, P., Norris, D., et al.2-aminothiazole as a novel kinase inhibitor template. Structure-activity relationship studies toward the discovery of N-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1-piperazinyl)]-2-methyl-4-pyrimidinyl]amino)]-1,3-thiazole-5-carboxamide (Dasatinib, BMS-354825) as a potent pan-Src kinase inhibitorJ. Med. Chem.49(23),6819-6823(2006)
Davis, M.I., Hunt, J.P., Herrgard, S., et al.Comprehensive analysis of kinase inhibitor selectivityNat. Biotechnol.29(11),1046-1051(2011)
Carter, T.A., Wodicka, L.M., Shah, N.P., et al.Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinasesProc. Natl. Acad. Sci. USA102(31),11011-11016(2005)
El-Amm, J., Freeman, A., Patel, N., et al.Bone-targeted therapies in metastatic castration-resistant prostate cancer: Evolving paradigmsProstate Cancer2013,1-10(2013)
Distler, J.H.W., and Distler, O.Intracellular tyrosine kinases as novel targets for anti-fibrotic therapy in systemic sclerosisRheumatology47(Suppl 5),10-11(2008)
McFarland, K.L., and Wetzstein, G.A.Chronic myeloid leukemia therapy: Focus on second-generation tyrosine kinase inhibitorsCancer Control16(2),132-140(2009)
